SCHEMBL345305

SCHEMBL345305

NC(CCCCNC(=O)c1ccccc1)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 5/20 0.58
HDAC2 Q92769 5/20 0.58
HDAC3 O15379 4/20 0.58
HDAC8 Q9BY41 4/20 0.58
HDAC6 Q9UBN7 4/20 0.58
HDAC4 P56524 3/20 0.58
HDAC7 Q8WUI4 3/20 0.58
HDAC10 Q969S8 3/20 0.58
HDAC11 Q96DB2 3/20 0.58
HDAC9 Q9UKV0 3/20 0.58
HDAC5 Q9UQL6 3/20 0.58
NAAA Q02083 1/20 0.58
EPHX2 P34913 1/20 0.55
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
POLB P06746 1/20 0.52
KMT2A Q03164 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.50
NCOR2 Q9Y618 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1242961 1.00 HDAC1 (0.58) HDAC1HDAC2HDAC3HDAC8HDAC6
SCHEMBL24130547 1.00 HDAC1 (0.58) HDAC1HDAC2HDAC3HDAC8HDAC6
SCHEMBL2237828 0.95 EPHX2 (0.57) HDAC1HDAC2HDAC3HDAC8HDAC6
SCHEMBL2237833 0.95 EPHX2 (0.57) HDAC1HDAC2HDAC3HDAC8HDAC6
SCHEMBL8192638 0.94 HDAC3 (0.52) HDAC1HDAC2HDAC3HDAC8HDAC6
SCHEMBL8194071 0.91 NPC1 (0.59) HDAC1HDAC2HDAC3HDAC8HDAC6
SCHEMBL1009383 0.90 OTC (0.49) HDAC1HDAC2HDAC3HDAC8HDAC6
SCHEMBL2464340 0.90 OTC (0.49) HDAC1HDAC2HDAC3HDAC8HDAC6
SCHEMBL10374328 0.89 MAPK14 (0.48) HDAC1HDAC2HDAC3HDAC8HDAC6
SCHEMBL4889040 0.89 HDAC1 (0.56) HDAC1HDAC2HDAC3HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3169403-B9 ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES PROTAGONIST THERAPEUTICS INC (US) 2024-07-03 EP disclosed
US-12018057-B2 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases JANSSEN BIOTECH, INC. (US) 2024-06-25 US disclosed
US-12018057-B2 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases JANSSEN BIOTECH, INC. (US) 2024-06-25 US disclosed
US-11753446-B2 Beta-hairpin peptidomimetics POLYPHOR AG (CH) 2023-09-12 US disclosed
US-20230203100-A1 COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE PEP2TANGO THERAPEUTICS INC. 2023-06-29 US disclosed
US-20230203100-A1 COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE PEP2TANGO THERAPEUTICS INC. 2023-06-29 US disclosed
US-20230129095-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES PROTAGONIST THERAPEUTICS, INC. (US) 2023-04-27 US disclosed
US-20230129095-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES PROTAGONIST THERAPEUTICS, INC. (US) 2023-04-27 US disclosed
US-11629171-B2 Beta-hairpin peptidomimetics SPEXIS AG (CH) 2023-04-18 US disclosed
WO-2023288313-A1 COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE PEP2TANGO THERAPEUTICS INC. (US) 2023-01-19 WO disclosed
US-20120283168-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY POLYPHOR AG (CH) 2012-11-08 US disclosed
EP-2501715-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY Polyphor Ag (CH) 2012-09-26 EP disclosed
CN-101258132-B (2, 5-Diketimidazolin-1-yl) -N-hydroxy-acetamides as metalloproteinase inhibitors JIANGSU HENGRUI MEDICINE CO 2012-04-25 CN disclosed
US-20120015994-A1 (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS MEDIVIR AB (SE) 2012-01-19 US disclosed
US-8022092-B2 (2,5-dioxoimidazolidin-1-yl)-N-hydroxy-acetamides as metalloproteinase inhibitors MEDIVIR AB (SE) 2011-09-20 US disclosed
WO-2011095607-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY POLYPHOR AG (CH) 2011-08-11 WO disclosed
WO-2011060937-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY POLYPHOR AG (CH) 2011-05-26 WO disclosed
US-20090215846-A1 (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS MEDIVIR AB (SE) 2009-08-27 US disclosed
CN-101258132-A (2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors MEDIVIR AB (CN) 2008-09-03 CN disclosed
CN-1109780-A Sustained-release preparation of anti-endothelin substance TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1995-10-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129095-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES IL23R, IL1RN, VIP HDAC1 2779/4885HDAC2 3108/4885HDAC3 1715/4885
US-20120283168-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY CCR10, CCR1, CCRL2 HDAC1 2385/4885HDAC2 2953/4885HDAC3 3755/4885
US-20230203100-A1 COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE IAPP, GPR119, GIPR HDAC1 3708/4885HDAC2 4430/4885HDAC3 3125/4885
US-12018057-B2 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases IL23R, IL1RN, VIP HDAC1 2779/4885HDAC2 3108/4885HDAC3 1715/4885
US-20120015994-A1 (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS MMP12, MMP13, MMP14 HDAC1 95/4885HDAC2 68/4885HDAC3 154/4885
US-11629171-B2 Beta-hairpin peptidomimetics POLL, POLQ, HBZ HDAC1 4283/4885HDAC2 4787/4885HDAC3 4505/4885
US-20090215846-A1 (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS MMP12, MMP13, MMP14 HDAC1 95/4885HDAC2 68/4885HDAC3 154/4885
US-11753446-B2 Beta-hairpin peptidomimetics POLL, BACE1, C1S HDAC1 2205/4885HDAC2 4308/4885HDAC3 4230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.